APTUM-TECHNOLOGIES
19.8.2019 14:02:06 CEST | Business Wire | Press release
Cogeco Peer 1, a managed hosting and cloud services provider, today announced it has changed its name to Aptum Technologies. The move follows the April 2019, acquisition of Cogeco Peer 1 by Digital Colony, a global investment firm dedicated to strategic opportunities in digital infrastructure.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190819005121/en/
“Aptum means ‘adaptability’ and reflects our heritage and vision for the future,” said Susan Bowen, Chief Executive Officer of Aptum. “As businesses face exponentially increasing volumes of information, and data becomes an integral part of their infrastructure, technology platforms must adapt and harness the power of data to enable better decision making, risk evaluation and customer engagement. We help organizations unlock the potential of their data by providing a robust infrastructure that enables customers to solve complex challenges and maximize the potential of their businesses.”
Headquartered in Toronto, Aptum will operate with two focused business units — Data Center and Fiber. The Data Center business will concentrate on enabling multi-cloud services for enterprises. The Fiber business will be Canada’s first independent, neutral-host provider of small cell and 5G infrastructure, and enterprise and wholesale fiber connectivity with an extensive metro fiber network across greater Toronto and Montreal.
With a 20-year heritage helping customers maximize technologies to store, manage, move and secure their critical data, Aptum is one of a select group of companies able to offer true hybrid infrastructure solutions with secure data center, cloud, connectivity and managed services across North and Central America, Europe, the Middle East and Africa.
Aptum is led by an experienced executive team that includes:
- Susan Bowen, Chief Executive Officer
- Shenif Visram, Chief Finance Officer
- Sanjay Sachdev, President and Head of Fiber
- Leighton Plumley, Chief Revenue Officer (Data Center Business Unit)
- Cindy Jordan-Ford, EVP Global Strategic Accounts & Alliances
- Jeremy Pease, Chief Operating Officer
- Scott Davis, Interim Chief Infrastructure Officer
- Paul Dyck, Vice President, Human Resources
Concurrent with the rebranding, Aptum has launched two new offerings that expand and enhance its customers’ hybrid cloud options:
- Managed Amazon Web Services (AWS) – reinforcing Aptum’s commitment to multi-cloud this new suite of AWS services complements Aptum’s existing Managed Azure and Managed Private Cloud offerings. Managed AWS services include consultation; architecture/design; solution build and configuration; migration; project management; ongoing service management and optimization; and 24/7 expert support. Managed AWS is available in Canada, the U.S. and the U.K.
- New Cloud Connect Availability – expansion of Cloud Connect, which offers a direct, dedicated and secure connection to cloud services. Cloud Connect is now available for AWS Direct Connect, Google Cloud Platform, ServiceNow, Salesforce, SAP and Oracle in addition to Microsoft ExpressRoute. The Cloud Connect expansion is available in all regions.
“The addition of these new cloud services is a perfect example of how Aptum is continually evolving to meet our customers’ changing needs,” Bowen said. “Every business has unique considerations, constraints and objectives that will be met by different solutions. Helping customers determine the correct platform for their unique requirements and then providing expert implementation is why businesses turn to Aptum.”
“As a rapidly growing AI products company, Element AI needed a true partner that could help us focus on our business growth rather than worrying about our data center infrastructure. For the past two years, Cogeco Peer 1 has consistently delivered,” said Ludwig Gamache, IT Director, Element AI. “Our requirements are different from most companies because of the compute-intensive nature of machine learning and AI algorithms – which generate more heat to dissipate and higher power demands than average customers. Element AI is now 35 times bigger than when we launched in 2016, and Cogeco Peer 1 has been able to adapt to solve our unique challenges. We look forward to continuing to evolve our IT infrastructure with Aptum as we grow."
Resources:
- Blog post: https://aptum.com/blog/welcome-to-aptum
- More about the executive team: https://aptum.com/company/leadership-team/
- Additional assets: Logo and executive headshots
About Aptum Technologies
Aptum Technologies enables customers to unlock the potential of their data infrastructure to drive tangible business outcomes and maximize the value of their technology investments. Aptum’s Data Center, Cloud, Hosting and Connectivity solutions, underpinned with expert Managed and Professional Services, offer genuine choice and adaptability combined with international reach spanning North America, Latin America and Europe. In Canada, through its Fiber business, Aptum is the first neutral host provider of turnkey small cell connectivity, augmenting an extensive metro network across Toronto and Montreal. Aptum is a portfolio company of Digital Colony, a global investment firm dedicated to strategic opportunities in digital infrastructure. For more information, visit www.aptum.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190819005121/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom